TABLE 14
PN 200-110 STUDY NO. 307

SUMMARY COMPARATIVE RESULTS FOR BLOOD PRESSURE AND PULSE
WEEK 5 - VALID AND PARTIALLY VALID PATIENTS

Variable	Treatment Group	No. Pts.	Baseline		Mean Change	S.D.	Adjusted Mean Change+	Treatment Period	
			Mean	S.D.				Mean	S.D.
Supine Systolic B.P. (mmHg)	PN 200-110	37	151.1	18.66	-14.1***	14.97	-17.1	135.0	13.57
	Propranolol	34	155.3	17.64	-17.2***	16.92	-16.1	138.2	18.68
Supine Diastolic B.P. (mmHg)	PN 200-110	37	104.2	7.43	-12.1***	7.80	-12.4	92.1	8.12
	Propranolol	34	105.7	7.34	-15.1***	8.37	-14.8	90.6	9.94
Supine Pulse (per min.)	PN 200-110	37	78.2	12.65	1.3	11.13	1.4	79.5	11.57
	Propranolol	34	77.7	10.87	-13.2***	11.40	-13.3***	64.5	12.82
Standing Systolic B.P. (mmHg)	PN 200-110	37	145.6	20.01	-15.9***	17.61	-16.5	129.7	15.68
	Propranolol	34	146.1	18.54	-17.3***	15.76	-16.6	130.9	19.45
Standing Diastolic B.P. (mmHg)	PN 200-110	37	104.9	9.79	-12.0***	10.97		93.0	8.93
	Propranolol	34	104.9	9.09	-14.4***	8.55		90.4	11.20
Standing Pulse (per min.)	PN 200-110	37	89.4	12.74	1.3	12.90	1.5	90.6	13.73
	Propranolol	34	88.4	12.32	-19.5***	11.67	-19.7***	68.8	14.35

(*)p<0.10, *p<.05, **p<.01, ***p<.001

+Presented only when analysis of covariance assumptions were met.

TABLE 15
PN 200-110 STUDY NO. 307

SUMMARY COMPARATIVE RESULTS FOR BLOOD PRESSURE AND PULSE
WEEK 6 - VALID AND PARTIALLY VALID PATIENTS

Variable	Treatment Group	No. Pts.	Baseline		Mean Change	S.D.	Adjusted Mean Change+	Treatment Period	
			Mean	S.D.				Mean	S.D.
Supine Systolic B.P. (mmHg)	PN 200-110	36	151.4	18.85	-19.8***	18.12		131.6	12.99
	Propranolol	33	155.7	17.81	-19.7***	15.01		135.9	20.35
Supine Diastolic B.P. (mmHg)	PN 200-110	36	104.5	7.40	-15.2***	8.03	-15.3	89.3	7.97
	Propranolol	33	105.3	7.22	-14.6***	8.60	-14.4	90.8	10.78
Supine Pulse (per min.)	PN 200-110	36	78.6	12.66	1.2	9.66	1.5	79.7	12.10
	Propranolol	33	77.0	10.42	-14.5***	10.58	-14.8***	62.5	9.36
Standing Systolic B.P. (mmHg)	PN 200-110	36	146.1	19.98	-18.7***	18.34		127.4	14.98
	Propranolol	33	148.4	18.75	-19.5***	15.78		128.8	20.65
Standing Diastolic B.P. (mmHg)	PN 200-110	36	105.3	9.68	-16.0***	11.26		89.3	9.12
	Propranolol	33	104.7	9.19	-15.4***	8.07		89.3	11.41
Standing Pulse (per min.)	PN 200-110	36	89.2	12.89	1.6	11.94	1.9	90.9	13.80
	Propranolol	33	87.8	12.10	-21.2***	9.73	-21.5***	66.7	9.63

(*)p<0.10, *p<.05, **p<.01, ***p<.001

+Presented only when analysis of covariance assumptions were met.

TABLE 16
PN 200-110 STUDY NO. 307

SUMMARY COMPARATIVE RESULTS FOR BLOOD PRESSURE AND PULSE
MEAN OVER PLATEAU PERIOD (WEEK 7-10) - VALID PATIENTS ONLY

Variable	Treatment Group	No. Pts.	Baseline		Mean Change	S.D.	Adjusted Mean Change*	Treatment Period	
			Mean	S.D.				Mean	S.D.
Supine Systolic B.P. (mmHg)	PN 200-110	33	151.7	19.50	-19.4***	14.59	-19.9	132.3	10.92
	Propranolol	29	153.8	16.29	-18.1***	12.45	-17.4	135.8	13.40
Supine Diastolic B.P. (mmHg)	PN 200-110	33	104.5	7.62	-15.1***	4.90	-15.2	89.4	5.36
	Propranolol	29	105.1	7.23	-15.5***	6.21	-15.4	89.6	7.32
Supine Pulse (per min.)	PN 200-110	33	78.1	13.15	2.9*	8.30	3.0	81.1	10.78
	Propranolol	29	77.7	10.67	-13.6***	10.56	-13.7	64.2	9.56
Standing Systolic B.P. (mmHg)	PN 200-110	33	146.5	20.31	-20.5***	17.13	-20.3	126.0	14.86
	Propranolol	29	145.7	15.98	-17.8***	10.65	-18.1	127.9	13.20
Standing Diastolic B.P. (mmHg)	PN 200-110	33	104.9	9.70	-14.6***	7.94		90.4	7.21
	Propranolol	29	103.6	8.63	-13.6***	5.91		69.9	8.75
Standing Pulse (per min.)	PN 200-110	33	88.9	13.36	3.1(*)	10.02	3.1	92.0	11.56
	Propranolol	29	88.8	11.65	-20.1***	9.34	-20.2	68.7	10.95

(*)p<0.10, *p<.05, **p<.01, ***p<.001

*Presented only when analysis of covariance assumptions were met.

TABLE 17
PN 200-110 STUDY NO. 307

SUMMARY COMPARATIVE RESULTS FOR BLOOD PRESSURE AND PULSE
ENDPOINT - PLATEAU PERIOD (WEEKS 7-10) - VALID AND PARTIALLY VALID PATIENTS

Variable	Treatment Group	No. Pts.	Baseline		Mean Change	S.D.	Adjusted Mean Change*	Treatment Period	
			Mean	S.D.				Mean	S.D.
Supine Systolic B.P. (mmHg)	PN 200-110	35	151.8	18.96	-18.3***	13.97	-19.0	133.5	14.89
	Propranolol	32	155.6	18.10	-16.2***	16.59	-15.5	139.4	21.52
Supine Diastolic B.P. (mmHg)	PN 200-110	35	104.6	7.49	-14.9***	5.42	-15.0	89.7	8.29
	Propranolol	32	105.5	7.24	-14.6***	10.01	-14.5	90.9	10.92
Supine Pulse (per min.)	PN 200-110	35	78.4	12.81	2.7	10.92	2.9	81.1	12.85
	Propranolol	32	77.5	10.27	-13.6***	12.08	-13.8	63.9	10.36
Standing Systolic B.P. (mmHg)	PN 200-110	35	146.9	19.80	-20.7***	16.05		126.1	15.63
	Propranolol	32	148.2	19.02	-17.5***	13.83		130.6	20.89
Standing Diastolic B.P. (mmHg)	PN 200-110	35	105.4	9.79	-13.7***	8.75		91.7	8.76
	Propranolol	32	104.6	9.30	-13.7***	9.61		90.8	13.59
Standing Pulse (per min.)	PN 200-110	35	89.0	13.03	4.2*	11.25	4.3	93.2	13.36
	Propranolol	32	88.4	11.86	-20.0***	10.98	-20.2	68.3	11.04

(*)p<0.10, *p<.05, **p<.01, ***p<.001

*Presented only when analysis of covariance assumptions were met.

TABLE 18
PN 200-110 STUDY NO. 307

SUMMARY COMPARATIVE RESULTS FOR BLOOD PRESSURE AND PULSE
ENDPOINT (WEEKS 1-10) - VALID AND PARTIALLY VALID PATIENTS

Variable	Treatment Group	No. Pts.	Baseline		Mean Change	S.D.	Adjusted Mean Change+	Treatment Period	
			Mean	S.D.				Mean	S.D.
Supine Systolic B.P. (mmHg)	PN 200-110	40	152.3	21.84	-18.5***	16.43		133.8	14.61
	Propranolol	38	155.8	18.09	-15.3***	19.26		140.6	24.08
Supine Diastolic B.P. (mmHg)	PN 200-110	40	104.8	7.66	-15.2***	7.17	-15.3	89.7	8.37
	Propranolol	38	105.8	7.58	-13.8***	11.03	-13.6	92.1	12.34
Supine Pulse (per min.)	PN 200-110	40	79.0	13.43	3.1(*)	10.86	3.4	82.1	13.07
	Propranolol	38	77.5	10.70	-12.5***	11.84	-12.8	65.0	10.61
Standing Systolic B.P. (mmHg)	PN 200-110	40	146.0	20.96	-20.5***	18.02		125.5	14.87
	Propranolol	38	148.0	18.30	-15.4***	16.96		132.6	22.13
Standing Diastolic B.P. (mmHg)	PN 200-110	40	105.0	10.13	-13.7***	9.58	-13.6	91.4	8.74
	Propranolol	38	104.6	9.37	-12.1***	11.81	-12.1	92.6	13.96
Standing Pulse (per min.)	PN 200-110	40	90.1	14.07	4.1*	11.35	4.4	94.2	13.15
	Propranolol	38	88.5	12.23	-19.3***	10.58	-19.7	69.2	11.24

(*)p<0.10, *p<.05, **p<.01, ***p<.001

+Presented only when analysis of covariance assumptions were met.

TABLE 19
PN 200-110 STUDY NO. 307

SUMMARY COMPARATIVE RESULTS FOR BLOOD PRESSURE AND PULSE
ENDPOINT - ALL PATIENTS

Variable	Treatment Group	No. Pts.	Baseline		Mean Change	S.D.	Adjusted Mean Change+	Treatment Period	
			Mean	S.D.				Mean	S.D.
Supine Systolic B.P. (mmHg)	PN 200-110	40	152.3	21.84	-19.3***	16.41		133.0	14.25
	Propranolol	38	155.8	18.09	-15.7***	19.48		140.1	24.33
Supine Diastolic B.P. (mmHg)	PN 200-110	40	104.8	7.66	-15.4***	7.18	-15.5	89.5	8.31
	Propranolol	38	105.8	7.58	-14.0***	11.14	-13.9	91.8	12.56
Supine Pulse (per min.)	PN 200-110	40	79.0	13.43	1.6	10.12	2.0	80.6	12.18
	Propranolol	38	77.5	10.70	-12.1***	12.13	-12.4	65.5	10.71
Standing Systolic B.P. (mmHg)	PN 200-110	40	146.0	20.96	-20.9***	18.34		125.1	14.63
	Propranolol	38	148.0	18.30	-15.7***	16.97		132.3	22.34
Standing Diastolic B.P. (mmHg)	PN 200-110	40	105.0	10.13	-13.6***	9.88		91.4	8.56
	Propranolol	38	104.6	9.37	-12.5***	11.58		92.2	14.31
Standing Pulse (per min.)	PN 200-110	40	90.1	14.07	3.1(*)	11.11	3.4	93.2	13.80
	Propranolol	38	88.5	12.23	-18.5***	11.13	-18.8	70.1	11.53

(*)p<0.10, *p<.05, **p<.01, ***p<.001

+Presented only when analysis of covariance assumptions were met.

TABLE 21A

PN 200-110 STUDY NO. 307

CARDIOVASCULAR EXAMINATION
NEWLY-OCCURRING AND WORSENING ABNORMALITIES*

Treatment Group	Patient Number	Type	Week	Specific Abnormality
PN 200-110	103	Extremities	6	1-2+ pretibial edema
	108	Extremities	10	Late day edema on legs, R>L
	109	Palpitations	10	
	112	Extremities	10	1+ edema
		Other	10	Muscle cramps
	152	Overall Appearance	1	Urticaria
	156	Heart Exam	6	Systolic murmur
	157	Extremities	1, 3	Rubor of feet, lower legs, hands; swollen feet and legs; rash-papules erythema
		Other	1	Redness of hands, feet, lower legs, face
	202	Cough	1	
	252	Other	10	Grade I hypertensive retinopathy (not noted on initial CV exam)**
	253	Dyspnea Supine	6	Sinusitis problem (not noted on initial CV exam)**
		Orthopnea	6	Sinusitis problem (not noted on initial CV exam)**
		Palpitations	6	ECG sinus problem (not noted on initial CV exam)**
	303	Cough	10	
		Heart Exam	10	Bigeminy

*Defined as an abnormality reported during the double-blind phase that was not present during the placebo run-in or an abnormality (reported during the placebo run-in) that worsened during the double-blind phase of the trial.

**Coded as a pre-existing abnormality.

TABLE 20A

PN 200-110 STUDY NO. 307

NEWLY-OCCURRING PHYSICAL EXAMINATION ABNORMALITIES

Treatment Group	Patient No.	Variable	Abnormality
PN 200-110	157	Skin	Non-pruritic rash-feet and legs
		Extremities	Feet and legs swollen; papules, erythema
	256	Ears, Nose, Throat	Full dentures (not noted on initial physical exam)*
	310	Skin	Face and neck flushed
		Heart	Mild tachycardia during episode
	311	Extremities	Pretibial edema
	314	Ears, Nose, Throat	Right ear canal-old cerumen
Propranolol	151	Eyes Abdomen	AV nicking Abdominal bruit
	158	Eyes Heart	AV crossing changes S4G-low volume pulses
	204	Heart	Bradycardia
	208	Eyes	Grade I retinopathy (noted as Grade 0 on initial physical exam)*
	251	Skin	Leg laceration
	304	Ears, Nose, Throat	Left TM obscured by cerumen (not noted on initial physical exam)*
	309	Extremities	Edema
	313	General Appearance	Moderate emaciation secondary to malnutrition
	404	Skin	Pruritic rash
	354	Abdomen	Liver-2 FB's-lower right costal margin
	451	Abdomen	Tenderness

*Coded as a pre-existing abnormality

TABLE 21

PN 200-110 STUDY NO. 307

CARDIOVASCULAR EXAMINATION
NEWLY-OCCURRING AND WORSENING ABNORMALITIES*

Abnormality	Patient Number		# of Patients with Newly-Occurring Abnormalities (%)	
	PN 200-110	Propranolol	PN 200-110	Propranolol
Chest Pain Exertion	314	309	1 (3)	1 (3)
Chest Pain at Rest	305	208	1 (3)	1 (3)
Dyspnea on Exertion	310		1 (3)	0 (0)
Dyspnea Sitting	310		1 (3)	0 (0)
Dyspnea Supine	253 310		2 (5)	0 (0)
Cough	202 303 412		3 (8)	0 (0)
Orthopnea	253		1 (3)	0 (0)
Syncope		312 313	0 (0)	2 (5)
Palpitations	109 253 310 314		4 (10)	0 (0)
Overall Appearance	152	313	1 (3)	1 (3)
Pulmonary Findings	410		1 (3)	0 (0)
Heart Exam	156 303 310	315	3 (8)	1 (3)
Abdominal Exam		151 204 354 451	0 (0)	4 (11)
Extremities	103 108 112 157	104 151 309	4 (10)	3 (8)
Other	112 157 252	404 406 411 451	3 (8)	4 (11)
NYHA Functional Class		110	0 (0)	1 (3)
Total Number of Patients With At Least One Newly-Occurring Abnormality/No. of Patients**	16/40 (40)	14/38 (35)		

*Defined as an abnormality reported during the double-blind phase that was not present during the placebo run-in or an abnormality (reported during the placebo run-in) that worsened during the double-blind phase.

**Only includes those patients who had at least one evaluation during the double-blind phase of the trial

TABLE 21A (Continued)

PN 200-110 STUDY NO. 307

CARDIOVASCULAR EXAMINATION
NEWLY-OCCURRING AND WORSENING ABNORMALITIES*

Treatment Group	Patient Number	Type	Week	Specific Abnormality
PN 200-110 (Continued)	305	Chest Pain at Rest	1,6	
	310	Dyspnea on Exertion	6	Has been present 60-90 minutes post-dose since study drug was increased to two tabs b.i.d.
		Dyspnea Sitting	6	
		Dyspnea Supine	6	
		Palpitations	6	
		Heart Exam	6	Rate 126
	314	Chest Pain Exertion	5	With A.M. dose, lasting one hour
		Palpitations	1	Occasionally "skips a beat", post A.M. dose of study drug
	410	Pulmonary Findings	6	Lungs - few dry rhonchi which clears with coughing
	412	Cough	10	Unproductive when lying down
Propranolol	104	Extremities	1, 6	Trace pretibial edema
	110	NYHA Functional Class	10	Slightly compromised
	151	Abdominal Exam	10	Abdominal bruit
		Extremities	10	Edema (not on initial CV exam)**
	204	Abdominal Exam	8	Obesity (not on initial CV exam)**
	208	Chest Pain at Rest	5	

*Defined as an abnormality reported during the double-blind phase that was not present during the placebo run-in or an abnormality (reported during the placebo run-in) that worsened during the double-blind phase of the trial.

**Coded as a pre-existing abnormality.

TABLE 21A (Continued)

PN 200-110 STUDY NO. 307

CARDIOVASCULAR EXAMINATION
NEWLY-OCCURRING AND WORSENING ABNORMALITIES*

Treatment Group	Patient Number	Type	Week	Specific Abnormality
Propranolol (Continued)	309	Chest Pain Exertion	10	
		Extremities	10	Edema
	312	Syncope	1	Lightheadness immediately after taking A.M. dose
	313	Syncope	1	Lightheadness one day, two hours post-dose
		Overall Appearance	6, 10	Slight cachexia, dietary problems
	315	Heart Exam	6	Sinus bradycardia
	354	Abdominal Exam	6	Liver 2FB lower right costal margin
	404	Other	10	Maculo-papular erythematous rash over the chest
	406	Other	1, 6	Dizziness
	411	Other	1	Cold symptoms (not noted on initial CV exam)**
	451	Abdominal Exam	7	Tenderness
		Other	10	Nausea after taking dose of study medication

*Defined as an abnormality reported during the double-blind phase that was not present during the placebo run-in or an abnormality (reported during the placebo run-in) that worsened during the double-blind phase of the trial.

**Coded as a pre-existing abnormality.

TABLE 22A

PN 200-110 STUDY NO. 307

LISTING OF NEWLY-OCCURRING ECG ABNORMALITIES BY PATIENT AND TREATMENT GROUP
(N=78)

Patient No.	Treatment Group	Week(s) Observed	Heart Rate at Week -4/ Week -1 (Beats/Min)	Type of Abnormality+	Specific Abnormality (Weeks - All if Blank)
102	PN 200-110	1, 6, 10		New Code (36)	Left atrial enlargement
105		1, 6, 10		New Code (38, 47)	Late transition, consider right ventricular enlargement (6); left axis deviation
		10		Rhythm	Premature ventricular beat one focus
108		6, 10		New Code (47)	Interatrial block; hypokalemia suspected
109		1, 6		New Code (14, 47)	Single premature ventricular contraction; hypokalemia suspected (6)
152		1		New Code (46)	T wave inversion I, AVL and lateral leads
153		6, 10		New Code (47)	Increased voltage; prominent U waves (10)
156		6		New Code (47)	Muscle artifact
157		3		New Code (47)	More prominent U waves
202		1, 6		New Code (1, 14, 47)	Atrial arrhythmia (1); premature ventricular contraction; baseline artifact (6)
207		1, 6, 10		New Code (46)	Non-specific ST-T wave changes
209		6		New Code (46)	Non-specific ST-T wave changes
212		10		Rhythm	Sinus arrhythmia
213		1		Rhythm	Sinus arrhythmia
		1, 6, 10		Overall	Sinus arrhythmia (1); non-specific ST-T wave changes (6, 10)
252		6, 10	64/62	New Code (3, 47)	Sinus bradycardia (HR=59) (10); QTc prolonged (6); left axis deviation, left atrial abnormality, early repolarization (10)
253		6, 10	80/84	Rhythm	No rhythm comment (6); sinus bradycardia (HR=62) (10)
		1, 8, 9, 10		New Code (2, 14)	Sinus tachycardia (HR=102, 112, 109) (1, 8, 9); premature ventricular contraction (8)
256		4, 5, 6, 10		New Code (47)	Inferolateral repolarization changes slightly less pronounced (coded as 46 on Weeks 6, 10); QTc long for rate (5)
303		10		New Code (17)	Ventricular bigeminy (10)
310		6	80/90	Rhythm	Sinus tachycardia (HR=108)
		6		Overall	Sinus tachycardia
316		6, 10	75/95	New Code (2)	Sinus tachycardia (HR=100)

+Rhythm = Rhythm coded as normal at baseline, abnormal during the double-blind period.
Overall = Overall interpretation coded as normal at baseline, abnormal during the double-blind period.

TABLE 22A (Continued)

PN 200-110 STUDY NO. 307

LISTING OF NEWLY-OCCURRING ECG ABNORMALITIES BY PATIENT AND TREATMENT GROUP
(N=78)

Patient No.	Treatment Group	Week(s) Observed	Heart Rate at Week -4/ Week -1 (Beats/Min)	Type of Abnormality+	Specific Abnormality (Weeks - All if Blank)
353	PN 200-110 (Continued)	1, 2, 6 10	70/98	Rhythm New Code (46)	Sinus tachycardia (HR=108, 110, 108) Non-specific ST-T wave changes
452		6, 10		New Code (46)	Non-specific ST-T wave changes
101	Propranolol	1, 5		New Code (36, 47)	Left atrial enlargement; QTc prolonged for rate-etiology (6)
104		6, 10		New Code (46, 47)	Non-specific ST-T wave changes; interatrial conduction delay (10)
106		1 1	72/63	Rhythm New Code (47)	Sinus bradycardia (HR=50) Non-diagnostic Q waves inferior
107		1, 6, 10		New Code (47)	Hypokalemia suspected (1, 6); interatrial block (10)
110		1, 6 6	60/67	Rhythm New Code (47)	Sinus bradycardia (HR=43, 48) Interatrial block, Q in lead III only
111		1 10	76/88	New Code (47) Rhythm	Inferior Q waves Sinus bradycardia (HR=50)
154		1, 6		New Code (45, 47)	Non-specific ST-T wave changes (1); interatrial block (6)
158		10 10	62/59	Rhythm Overall	Sinus bradycardia (HR=46) Increased bradycardia
201		1, 6, 10	90/68	New Code (3, 4, 47)	Sinus bradycardia (HR=55) (6); premature atrial contraction (10); significant axis changes during study (1); interventricular conduction delay, Q waves lead III (10)
204		6, 8	80/78	New Code (3, 14, 22, 27 47)	Sinus bradycardia (HR=50, 54); premature ventricular contraction (6); borderline 1° heart block; left anterior heart block (8); poor R wave progression; Q wave II, III and AVF (8)
205		1, 6, 10	88/86	New Code (3, 47)	Sinus bradycardia (HR=56, 59) (1, 10); QTc prolonged (6)
208		1, 5		New Code (46, 47)	Non-specific ST-T wave changes (1); repolarization changes I, AV, and lateral leads, axis shift leftward 30-0° (5)
211		6, 10		New Code (46)	Non-specific ST-T wave changes
14		1, 6, 10	74/62	New Code (3, 22)	Sinus bradycardia (HR=45, 47, 46); 1° AV block (6)

0461

+Rhythm = Rhythm coded as normal at baseline, abnormal during the double-blind period.
Overall = Overall interpretation coded as normal at baseline, abnormal during the double-blind period.
New Code = Code which does not occur during baseline and does occur during the double-blind period at an evaluation with at least one of the following: 1) abnormal rhythm, 2) abnormal overall interpretation, or 3) significant difference from previous ECG.

07-02509

TABLE 22A (Continued)

PN 200-110 STUDY NO. 307

LISTING OF NEWLY-OCCURRING ECG ABNORMALITIES BY PATIENT AND TREATMENT GROUP
(N=78)

Patient No.	Treatment Group	Week(s) Observed	Heart Rate at Week -4/ Week -1 (Beats/Min)	Type of Abnormality+	Specific Abnormality (Weeks - All if Blank)
251	Propranolol (Continued)	1 1, 3, 6, 10	62/64	Rhythm New Code (3, 37)	Sinus arrhythmia Sinus bradycardia (HR=48, 45, 46) (3, 6, 10); borderline left ventricular hypertrophy (1)
254		1		New Code (47)	Early repolarization
255		6		Rhythm	Heart rate (64) slower than previous tracing
		10 1	76/88	Rhythm New Code (47)	Sinus bradycardia (HR=60) Left axis deviation; late R wave transition
301		1		New Code (14)	Premature ventricular contraction
313		1, 10 1	72/96	Rhythm New Code (45)	Sinus bradycardia (HR=57, 55) ST changes not as prominent
315		1, 2, 6, 7 7	60/68	Rhythm New Code (47)	Sinus bradycardia (HR=46, 54, 47, 53); 1st degree AV block (6) Borderline prolonged PR interval
401		1	63/72	New Code (3)	Sinus bradycardia (HR=58)
407		1, 2, 6, 10	77/63	Rhythm	Sinus bradycardia (HR=59, 51, 54, 56) Rare premature ventricular contraction (2, 6, 10)
409		1, 6, 10	74/61	Rhythm	Sinus bradycardia (HR=58, 53, 56)
451		1, 6	76/78	Rhythm	Sinus bradycardia (HR=59, 58)

+Rhythm = Rhythm coded as normal at baseline, abnormal during the double-blind period.
Overall = Overall interpretation coded as normal at baseline, abnormal during the double-blind period.
New Code = Code which does not occur during baseline and does occur during the double-blind period at an evaluation with at least one of the following: 1) abnormal rhythm, 2) abnormal overall interpretation, or 3) significant difference from previous ECG.

TABLE 23
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR ECG VARIABLES

Variable	Treatment Group	Completers Only									All Patients				
			Baseline		Week 1		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
Ventricular Rate* (per min.)	PN 200-110	31	77.4	14.58	3.8(*)	11.98	0.5	10.03	2.8	10.71	38	77.7	14.76	3.6*	10.66
	Propranolol	28	77.7	13.17	-12.8***	13.60	.1***	9.33	-15.0***	11.75	37	77.5	13.33	-14.0***	11.07
P-R Interval (sec.)	PN 200-110	31	0.164	0.023	-0.001	0.013	0.000	0.018	0.001	0.017	38	0.166	0.025	0.000	0.016
	Propranolol	28	0.172	0.028	0.006(*)	0.017	0.007*	0.014	0.002	0.019	37	0.171	0.026	0.003	0.019
QRS Duration (sec.)	PN 200-110	31	0.086	0.009	0.001	0.010	0.002	0.011	-0.002	0.014	38	0.086	0.009	-0.002	0.014
	Propranolol	28	0.091	0.013	-0.003*	0.008	0.000	0.012	-0.002	0.013	37	0.089	0.014	0.000	0.013
QT Interval (sec.)	PN 200-110	31	0.381	0.031	-0.002	0.022	0.007(*)	0.019	-0.009*	0.020	38	0.377	0.034	-0.006	0.026
	Propranolol	28	0.386	0.031	0.014	0.029	0.022**	0.040	0.018**	0.029	37	0.382	0.033	0.017**	0.026

(*)p<0.10, *p<.05, **p<.01, ***p<.001

*Only the ventricular rate was analyzed as the atrial rate is equal to the ventricular rate.

Table 23

0463

0:0D5411

TABLE 27
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR HEMATOLOGY LAB DATA

Variable (Normal Range)	Treatment Group	Completers Only+							All Patients				
			Baseline		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
Hemoglobin gm/dl (11.9-17.6)	PN 200-110	32	14.5	1.83	-0.09	0.94	-0.25	1.05	39	14.5	1.71	-0.12	1.06
	Propranolol	27	14.7	1.53	-0.33(*)	0.83	-0.02	1.13	37	14.6	1.49	-0.20	1.13
Hematocrit % (37.0-54.0)	PN 200-110	32	43.8	4.75	-0.78	3.01	-0.74	3.24	39	43.9	4.45	-0.21	3.52
	Propranolol	27	45.3	4.20	-1.44*	3.07	-0.99	4.03	37	45.0	4.27	-1.30*	3.90
WBC x 10^3 cu mm (3.9-11.4)	PN 200-110	32	7.2	2.01	0.23	1.71	0.20	1.23	39	7.3	1.98	0.35	1.33
	Propranolol	27	6.9	2.06	0.21	1.50	0.22	1.21	37	7.1	2.02	0.07	1.10
Neutrophils % (42-81)	PN 200-110	32	61.4	8.34	-2.38	8.41	-2.03	7.02	39	61.8	8.41	-1.41	6.92
	Propranolol	27	57.7	9.91	0.93	9.90	0.11	7.97	37	57.9	10.13	-0.11	7.97
Lymphocytes % (10-47)	PN 200-110	32	29.9	8.79	-0.38	11.11	1.53	7.00	39	29.4	8.81	1.03	6.93
	Propranolol	27	33.1	10.06	-0.93	10.05	0.37	8.19	37	33.3	10.71	-0.05	8.97
Monocytes % (0-10)	PN 200-110	32	6.3	3.16	2.25	12.56	0.25	3.32	39	6.6	2.99	0.10	3.14
	Propranolol	27	6.3	2.23	-0.74	3.34	-0.59	3.14	37	6.1	2.17	0.00	3.19

(*)$p<0.10$, *$p<.05$, **$p<.01$, ***$p<.001$
+The following patients were excluded from the completed patients analysis due to insufficient data: Pats. 101, 105, 106, and 202.

0464 07-02515

TABLE 27 (Continued)
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR HEMATOLOGY LAB DATA

Variable (Normal Range)	Treatment Group	Completers Only+							All Patients				
			Baseline		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
Eosinophils % (0-8)	PN 200-110	32	2.1	1.80	0.22	1.34	-0.03	1.43	39	1.9	1.65	-0.03	1.35
	Propranolol	27	2.3	1.63	0.52(*)	1.48	0.00	1.11	37	2.2	1.58	-0.03	1.01
Basophils % (0-2)	PN 200-110	32	0.6	0.71	0.19	0.97	0.22	0.94	39	0.6	0.71	0.18	0.94
	Propranolol	27	0.7	0.61	0.15	0.95	0.26	0.81	37	0.7	0.57	0.14	0.79
Bands % (0-5)	PN 200-110	6	0.0	0.00	0.33	0.52	0.00	0.00	20	0.2	0.37	-0.05	0.51
	Propranolol	12	0.2	0.39	0.00	0.43	0.00	0.60	24	0.1	0.34	0.08	0.50

(*)p<0.10, *p<.05, **p<.01, ***p<.001
+The following patients were excluded from the completed patients analysis due to insufficient data: Pats. 101, 105, 106, and 202.

TABLE 27 (Continued)
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR URINALYSIS DATA

Variable (Normal Range)	Treatment Group	Completers Only*							All Patients				
			Baseline		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
Specific Gravity (1.001-1.035)	PN 200-110	33	1.022	0.005	-0.001	0.006	-0.001 (↓)	0.007	39	1.022	0.005	-0.001 (↓)	0.007
	Propranolol	26	1.019	0.005	0.000	0.006	0.003*	0.006	37	1.020	0.005	0.002	0.007
pH (5-7)	PN 200-110	33	5.3	0.59	0.06	0.61	0.15 (↓)	0.71	39	5.3	0.56	0.15 (↓)	0.67
	Propranolol	26	5.5	0.71	-0.35*	0.69	-0.27(*)	0.67	37	5.5	0.65	-0.22*	0.58

(*)p<0.10, *p<.05, **p<.01, ***p<.001
*THE FOLLOWING PATIENTS WERE EXCLUDED FROM THE COMPLETED PATIENTS ANALYSIS DUE TO INSUFFICIENT DATA: PATS. 101, 104, 105, AND 106.

Table 27 (cont'd.)

TABLE 27 (Continued)
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR CHEMISTRY DATA

Variable (Normal Range)	Treatment Group	Completers Only+							All Patients				
			Baseline		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
Calcium mg/dl (8.8-10.5)	PN 200-110	33	9.7	0.49	0.02	0.42	-0.04	0.43	39	9.7	0.47	0.03	0.46
	Propranolol	26	9.7	0.46	-0.10	0.42	-0.07	0.41	37	9.7	0.45	-0.07	0.44
Inorganic Phosphorus mg/dl (2.2-4.6)	PN 200-110	33	3.1	0.59	-0.05	0.73	-0.10	0.58	39	3.2	0.57	-0.10	0.59
	Propranolol	26	3.4	0.54	0.10	0.58	0.09	0.44	37	3.4	0.50	0.02	0.44
BUN mg/dl (6-23)	PN 200-110	33	15.8	5.57	-0.12	3.91	-1.09	3.72	39	15.5	5.67	-0.39	4.52
	Propranolol	26	13.3	4.92	0.89	3.54	1.46	4.42	37	13.2	4.36	1.38(*)	3.93
Uric Acid mg/dl (2.2-8.3)	PN 200-110	33	6.8	1.75	-0.32*	0.89	-0.30	1.15	39	6.6	2.00	-0.25	1.07
	Propranolol	26	7.1	1.66	0.19(*)	1.09	0.2(*)	1.06	37	7.2	1.70	0.02	1.10
Glucose mg/dl (65-130)	PN 200-110	33	109.3	24.48	11.12	67.11	3.73	45.60	39	106.3	24.21	5.56	43.27
	Propranolol	27	107.4	26.99	13.56*	30.77	10.41	31.85	37	110.3	30.33	13.87*	38.65
Total Protein gm/dl (6.4-8.1)	PN 200-110	33	7.5	0.46	-0.05	0.41	-0.06	0.49	39	7.4	0.48	-0.01	0.54
	Propranolol	26	7.6	0.59	-0.20*	0.40	-0.17(*)	0.42	37	7.7	0.53	-0.17*	0.40

(*)p<0.10, *p<.05, **p<.01, ***p<.001
+The following patients were excluded from the completed patients analysis due to insufficient data: Pats. 105 and 106.

Table 27 (cont'd.

TABLE 27 (Continued)
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR CHEMISTRY DATA

Variable (Normal Range)	Treatment Group	Completers Only+							All Patients				
			Baseline		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
Albumin gm/dl (3.7-5.0)	PN 200-110	33	4.2	0.34	-0.04	0.30	-0.02	0.34	39	4.2	0.33	0.04	0.34
	Propranolol	26	4.2	0.37	-0.07	0.28	-0.07	0.27	37	4.2	0.36	-0.08(*)	0.27
Total Bilirubin mg/dl (0.2-1.6)	PN 200-110	33	0.6	0.25	-0.04	0.22	-0.05	0.24	40	0.5	0.23	-0.04	0.23
	Propranolol	27	0.6	0.26	-0.04	0.27	-0.03	0.17	38	0.6	0.25	-0.03	0.17
Cholesterol mg/dl (120-290)	PN 200-110	33	222.5	36.38	-0.21	28.10	-3.85	23.42	39	220.3	35.54	-1.62	25.54
	Propranolol	26	214.6	36.77	4.39	26.26	2.12	23.08	37	218.6	35.88	1.27	25.27
Alkaline Phosphatase U/L (10-45)	PN 200-110	33	27.5	8.98	2.49(*)	7.37	0.46	5.82	40	26.2	8.82	0.58	5.40
	Propranolol	27	29.1	9.09	1.70	7.50	0.70	9.02	38	30.7	10.91	0.05	9.18
LDH U/L (110-250)	PN 200-110	31	172.1	36.75	3.55	28.23	-3.77	28.85	40	171.3	34.49	2.53	34.82
	Propranolol	26	184.7	50.75	-18.04*	40.32	-6.23	56.19	38	190.1	54.15	-16.13	42.40
SGOT U/L (10-50)	PN 200-110	33	28.0	9.62	3.06	13.89	-0.12	7.18	40	27.4	9.82	0.53	8.15
	Propranolol	27	35.1	24.79	-6.33*	14.32	-2.96	13.99	38	36.3	23.64	-0.63	19.62

(*)p<0.10, *p<.05, **p<.01, ***p<.001
+The following patients were excluded from the completed patients analysis due to insufficient data: Pats. 105 and 106.

Table 27 (cont'd.)

TABLE 27 (Continued)
PN 200-110 STUDY NO. 307

SUMMARY OF COMPARATIVE RESULTS FOR CHEMISTRY DATA

Variable (Normal Range)	Treatment Group	Completers Only*							All Patients				
			Baseline		Week 6		Week 10			Baseline		Endpoint	
		N	Mean	S.D.	Mean Change	S.D.	Mean Change	S.D.	N	Mean	S.D.	Mean Change	S.D.
sGPT U/L (5-55)	PN 200-110	33	27.7	18.73	5.09	19.30	-1.24	12.81	40	27.2	17.81	-0.68	13.51
	Propranolol	27	26.2	16.47	-3.67	11.57	-1.33	8.61	38	29.2	20.17	3.18	21.25
Sodium mEq/l (134-143)	PN 200-110	33	138.7	2.51	-1.42 (+)	5.11	-0.88(*) (*)	2.95	39	138.8	2.43	-0.74 (+)	2.92
	Propranolol	27	138.1	2.41	0.59	2.85	0.59	2.97	37	138.2	2.46	0.57	2.95
Potassium mEq/l (3.5-5.3)	PN 200-110	32	3.7	0.52	-0.18*	0.42	-0.05	0.41	39	3.7	0.51	-0.03	0.39
	Propranolol	27	3.7	0.51	-0.04	0.50	0.05	0.52	37	3.6	0.53	0.14(*)	0.49
Chloride mEq/l (96-107)	PN 200-110	33	99.5	2.90	-0.82	3.75	0.49	3.	39	99.4	2.84	0.23	3.07
	Propranolol	27	98.0	3.98	1.85*	4.37	1.52	4.64	37	97.6	3.70	1.60*	4.06
CO_2 mEq/l (25-32)	PN 200-110	31	26.6	2.25	0.16	2.91	0.13	2.34	38	26.7	2.83	0.15	2.13
	Propranolol	25	27.2	4.20	0.66	3.30	0.77	3.88	37	27.2	3.77	0.98	3.72
Creatinine mg/dl (.6-1.3)	PN 200-110	33	1.0	0.22	0.06(*)	0.22	0.03	0.24	39	1.0	0.27	0.04	0.23
	Propranolol	26	1.1	0.24	0.00	0.17	0.03	0.15	37	1.1	0.23	0.04	0.14

(+)p<0.10, *p<.05, **p<.01, ***p<.001

*The following patients were excluded from the completed patients analysis due to insufficient data: Pats. 105 and 106.

Table 27 (cont'd.)

TABLE 28

PN 200-110 STUDY NO. 307

LABORATORY DATA - HEMATOLOGY

NEWLY-OCCURRING LABORATORY ABNORMALITIES+

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit	Baseline (Wk. -1)	Active Treatments++						Abnormal High (H) or Abnormal Low (L)
					Wk. 6	Wk. 7	Wk. 8	Wk. 9	Wk. 10	Follow-up	
PN 200-110	102	Hemoglobin gm/dl (11.9-17.6)	10.6	10.2	11.9		11.6	10.4	9.7	9.8	L
		Hematocrit % (37-54)	34	33	36		37	33	31	32	L
		WBC x 10^3 cu mm (3.9-11.4)	9.7	11.9	6.6		21.0	9.6	10.4	7.6	H
		Platelet Est. (Normal)	Normal	Normal			Increase	Increase	Increase	Increase	H
	206	Monocytes % (0-10)	6	11	15			7			H
	252	Hemoglobin gm/dl (11.9-17.6)	12.3	11.9	9.9*				11.4		L
		Hematocrit % (37-54)	38	38	30*				37		L
		Neutrophils % (42-81)	46	45	25				54		L
		Lymphocytes % (10-47)	48	47	0				39		L
		Monocytes % (0-10)	4	6	75				6		H
	352	Basophils % (0-2)	1	0	2				3		H
	408	Monocytes % (0-10)	1	7		13			9		H

+Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.

++Underlined laboratory values indicate an abnormality.

*Lab abnormality is considered clinically significant by the investigator.

TABLE 28

TABLE 28 (Continued)
PN 200-110 STUDY NO. 307

LABORATORY DATA - HEMATOLOGY
NEWLY-OCCURRING LABORATORY ABNORMALITIES*

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit	Baseline (Wk. -1)	Active Treatments**						Abnormal High (H) or Abnormal Low (L)
					Wk. 6	Wk. 7	Wk. 8	Wk. 9	Wk. 10	Follow-up	
Propranolol	107	WBCx10^3 cu mm (3.9-11.4)	3.5		4.2				3.1	3.6	L
	204	Monocytes % (0-10)	7	6	15		9				H
	251	Basophils % (0-2)	1	1	3				2		H
	304	Basophils % (0-2)	0	1	3				2		H

*Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.

**Underlined laboratory values indicate an abnormality.

TABLE 28

0471
L-02522

LABORATORY DATA - URINALYSIS
NEWLY-OCCURRING LABORATORY ABNORMALITIES*

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit	Baseline (Wk. -1)	Active Treatments**								Abnormal High (H) or Abnormal Low (L)
					Wk. 1	Wk. 3	Wk. 6	Wk. 7	Wk. 8	Wk. 9	Wk. 10	Follow-up	
PN 200-110	102	WBC/HPF (0-5)	2-5	0-2			2-5		5-10	0-2	2-5	0-2	H
		Glucose (0-0)	0	0			3		3	3	0	3	H
		Acetone (0-0)	0	0			0		0	1	0	0	H
	108	WBC/HPF (0-5)	2-5	2-5			10-30				0-2		H
	152	Albumin (0-0)	0	0	1								H
	153	WBC/HPF (0-5)		0-2		0-2					10-30		H
	156	WBC/HPF (0-5)		None			5-10				2-5*		H
	157	RBC/HPF (0-2)	None	None		5-10							H
	203	Cast/HPF (0-0)	None	None			None				0-2		H
	209	RBC/HPF (0-2)	None	None			None				2-5*		H
	352	RBC/HPF (0-2)	None	None			30-70*				None		H
		Albumin (0-0)	0	0			1*				0		H
	353	WBC/HPF (0-5)	0-2	0-2			5-10				0-2		H
	402	RBC/HPF (0-2)	0-2	None			0-2				5-10		H

*Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.

**Underlined laboratory values indicate an abnormality.

*Lab abnormality is considered clinically significant by the investigator.

TABLE 28

TABLE 2 (continued)
FN 200-1% . 307

LABORATORY DATA - URINALYSIS
NEWLY-OCCURRING LABORATORY ABNORMALITIES*

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit**	Baseline (Wk. -1)**	Active Treatments**								Abnormal High (H) or Abnormal Low (L)
					Wk. 1	Wk. 2	Wk. 3	Wk. 5	Wk. 6	Wk. 7	Wk. 10	Follow-up	
Propranolol	101	WBC/HPF (0-5)	2-5	None	5-10						2-5		H
	106	Cast/HPF (0-0)	None	None		0-2			None				H
		WBC/HPF (0-5)	2-5	None		5-10			5-10				H
		Glucose (0-0)	0	0		0			3				H
	111	WBC/HPF (0-5)		0-2					2-5		5-10		H
	151	RBC/HPF (0-2)	None	None					5-10		None		H
	154	Albumin (0-0)		0					1		0		H
	158	Cast/HPF (0-0)	None	None				None			0-2		H
		WBC/HPF (0-5)	None	0-2				2-5			5-10		H
	211	WBC/HPF (0-5)	0-2	0-2					5-10		0-2		H
	254	Glucose (0-0)	0	0					2		2		H
	255	Glucose (0-0)	0	0					2		0		H

*Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.

**Underlined laboratory values indicate an abnormality.

No abnormality is considered to be clinically significant by the investigator.

TABLE 28

U-02524
0472

TABLE 28 (d)
PN 200-110 . J. 307

LABORATORY DATA - URINALYSIS
NEWLY-OCCURRING LABORATORY ABNORMALITIES*

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit**	Baseline (Wk. -1)**	Active Treatments**								Abnormal High (H) or Abnormal Low (L)
					Wk. 1	Wk. 2	Wk. 3	Wk. 5	Wk. 6	Wk. 7	Wk. 10	Follow-up	
Propranolol (Con't)	301	RBC/HPF (0-2)	0-2	None					2-5	None	None		H
	312	RBC/HPF (0-2)	10-30*	10-30*	100-200*		0-2						H***
	313	Cast/HPF (0-0)	None	None					None		0-2		H
	354	Cast/HPF (0-0)	None	None					0-2		None		H

*Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.

**Underlined laboratory values indicate an abnormality.

***Abnormal at baseline and worsening by at least 15%.

*Lab abnormality is considered to be clinically significant by the investigator.

TABLE 28

0474

TABLE 28 (Continued)
PN 200-110 STUDY NO. 307

LABORATORY DATA - CHEMISTRY
NEWLY-OCCURRING LABORATORY ABNORMALITIES*

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit**	Baseline (Wk. -1)**	Active Treatments** Wk. 1	Wk. 2	Wk. 3	Wk. 4	Wk. 5	Wk. 6	Wk. 7	Wk. 8	Wk. 9	Wk. 10	Follow-up 1	2	3	Abnormal High (H) or Abnormal Low (L)
PN 200-110	102	Glucose mg/dl (65-130)	172	160						520*		552*	434*	385*	179			H***
		Albumin gm/dl (3.7-5.0)	3.8	3.6						3.3		3.3	3.0	3.2	3.2			L
		LDH U/L (110-250)	189	180	302	286	197		259	196		180	188		176			H
		SGOT U/L (10-50)	18	24	13	31	18		129*	46	53	21	32	34	17			H
		SGPT U/L (5-55)	10	12	20	27	13		128*	67	67	31	25	26	16			H
		Potassium mEq/l (3.5-5.3)	4.5	3.0						3.3		2.9	3.5	3.4	3.1			L
	105	LDH U/L (110-250)		211	200	298	199	216	226	220	202	211	212		218			H
	108	Potassium mEq/l (3.5-5.3)	3.3	3.2						2.8*				3.8				L
	112	Glucose mg/dl (65-130)	124	112	110					193*	121			138				H
	152	LDH U/L (110-250)	217	204	322	194												H
		BUN mg/dl (6-23)	29	27	42	23												H***
		Creatinine mg/dl (0.6-1.3)	1.8	1.9	2.2	1.7												H***
	153	SGOT U/L (10-50)		16			67			18	37			22				H
		SGPT U/L (5-55)		10			97			23	20			2				H

*Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.

**Underlined laboratory values indicate an abnormality.

***Abnormal at baseline and worsening by at least 15%.

*Lab abnormality is considered clinically significant by the investigator.

U-00526

04 FE

table 28

TABLE 28 (Continued)
PN 200-110 STUDY NO. 307

LABORATORY DATA - CHEMISTRY
NEWLY-OCCURRING LABORATORY ABNORMALITIES*

Treatment Group	Pat. No.	Variable (Normal Range)	Initial Visit**	Baseline (Wk. -1)**	Active Treatments** Wk. 1	Wk. 2	Wk. 3	Wk. 4	Wk. 5	Wk. 6	Wk. 7	Wk. 8	Wk. 9	Wk. 10	Follow-up 1	2	3	Abnormal High (H) or Abnormal Low (L)
Propranolol (Con't)	306	LDH U/L (110-230)	207	231	226	365°	216	183	166	177	190	185	186	174	179			H
	308	Glucose mg/dl (65-130)	145	104						190				99				H
		LDH U/L (110-250)	230	261	[illegible]	234	231	260	302	290°	274	316	276	254°				H
	312	Alkaline Phosphatase U/L (10-45)	54	55	51	62	66											H***
	313	BUN mg/dl (6-23)	13	17						22				28°				H
		Uric Acid mg/dl (2.2-8.3)	6.8	7.8						9.6°				8.6				H
		Alkaline Phosphatase U/L (10-45)	65	60	75	63	63	66	63	67	64	70	90	87				H***
	351	SGOT U/L (10-50)	33	45	35	51	47	42	64									H
		SGPT U/L (5-55)	58	78	78	101	75	74	87									H***
	354	Glucose mg/dl (65-130)	95	79						55				75				L
		Alkaline Phosphatase U/L (10-45)	30	39		30	50	14	29	44	52	43	41	53				H
	404	SGPT U/L (5-55)	41	47	45		67	43	66	59	45	35	54	47	17			[illegible]

*Defined as all pre-dose evaluations being normal and at least one abnormal post-dose evaluation based on adjusted normal limits or an abnormal baseline value that worsened by at least 15%.
**Underlined laboratory values indicate an abnormality.
***Abnormal at baseline and worsening by at least 15%.
[illegible] abnormality is considered clinically significant by the investigator.

TABLE 28

TABLE 29
PN 200-110 STUDY NO. 307

FREQUENCY OF NEWLY-OCCURRING OR WORSENING
LABORATORY ABNORMALITIES

HEMATOLOGY AND URINALYSIS

Variable	Treatment Group	
	PN 200-110 (N=40)	Propranolol (N=38)
Hematology		
Hemoglobin gm/dl		
LOW:	2*	0
Hematocrit %		
LOW:	2*	0
WBC x 10^3 cu mm		
HIGH:	1	0
LOW:	0	1
Neutrophils %		
LOW:	[illegible]	0
Lymphocytes %		
LOW:	1	0
Monocytes %		
HIGH:	3	1
Basophils %		
HIGH:	1	2
Platelet Estimate		
HIGH:	1	0
Urinalysis		
Casts/HPF		
HIGH:	1	4
WBC/HPF		
HIGH:	5	5
RBC/HPF		
HIGH:	4**	3*
Albumin		
HIGH:	2*	1
Glucose		
HIGH:	1	3
Acetone		
HIGH:	1	0

NOTE: Asterisk denotes a patient with a clinically significant abnormality.

TABLE 29 (Continued)
PN 200-110 STUDY NO. 307

FREQUENCY OF NEWLY-OCCURRING OR WORSENING
LABORATORY ABNORMALITIES

CHEMISTRY

Variable	Treatment Group	
	PN 200-110 (N=40)	Propranolol (N=38)
Chemistry		
Inorganic Phosphorus mg/dl LOW:	1	0
Glucose mg/dl		
HIGH:	4***	6**
LOW:	0	1
Albumin gm/dl		
LOW:	1	0
Total Bilirubin mg/dl		
HIGH:	1*	0
Cholesterol mg/dl		
HIGH:	1	1
Alkaline Phosphatase IU/L HIGH:	3*	3
LDH IU/L		
HIGH:	6**	5***
SGOT IU/L		
HIGH:	8***	4
SGPT IU/L		
HIGH:	10***	8**
Potassium mEq/l		
LOW:	3*	4*
HIGH:	0	1**
BUN mg/dl		
HIGH:	2	2*
Creatinine mg/dl		
HIGH:	4*	0
Uric Acid mg/dl		
HIGH:	0	1*

NOTE: Asterisk denotes a patient with a clinically significant abnormality.

TABLE 30

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence*	Worst Occurrence**
PN 200-110	102	Tachycardia	5 - Mild	6 - Mild	
		Visual Disturbance	8 - Mild		
	103	Epistaxis	-2 - Moderate		
		Edema	5 - Mild	7 - Mild	6 - Moderate
	108	Headache	1 - Mild		
		Dizziness	5 - Mild	6 - Mild	
		Edema	10 - Moderate		
	109	Insect Bite	-3 - Mild		
		Cardiac (Misc. Abnormality)	9 - Mild	10 - Mild	
	112	Edema	10 - Mild		
		Cramps, Muscle	10 - Mild		
	152	Hives	1 - Severe	2 - Severe	
	153	Headache	-2 - Moderate	-1 - Mild	
	157	Edema	1 - Moderate	3 - Moderate	
		Headache	1 - Severe		
		Rash	3 - Moderate		
		Abdominal Discomfort	3 - Moderate		
	202	Coughing	1 - Mild	2 - Mild	
		Cramps, Leg/Feet	2 - Mild	4 - Mild	
		Cramps, Muscle	5 - Mild	8 - Mild	
	203	Upper Respiratory Infection	-3 Mild	7 - Moderate	5 - Moderate
		Coughing	-1 - Mild	5 - Mild	
	206	Headache	-2 - Moderate	5 - Mild	
		Rectal Bleeding	-1 - Moderate		
	207	Headache	-2 - Mild	-1 - Moderate	
		Sunburn	-1 - Moderate		
		Upper Respiratory Infection	4 - Mild	10 - Mild	
		Cramps, Legs/Feet	2 - Mild	3 - Mild	
		Diarrhea	10 - Mild		

*Presented only if there is a multiple occurrence.

**Presented only if different from information recorded under first or last occurrence.

TABLE 30 (Continued)

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence*	Worst Occurrence**
PN 200-110	209	Dizziness	-2 - Mild		
		Headache	-2 - Mild		
		Hypokalemia	-1 - Mild		
	212	Cold Symptoms	6 - Moderate	7 - Mild	
		Throat Discomfort	6 - Moderate	7 - Mild	
	252	Headache	-3 - Moderate		
		Toothache	-1 - Moderate	1 - Severe	
		Joint Pain	8 - Mild		
		Chest Pain	9 - Mild		
	253	Headache	-2 - Mild	5 - Mild	
		Fatigue	-2 - Mild	10 - Mild	
		Chest Pain	-2 - Mild	3 - Mild	
		Flushing	-1 - Mild	10 - Mild	8 - Moderate
		Cramps, Muscle	-1 - Mild	1 - Mild	
		Pruritus	5 - Moderate	10 - Mild	
		Tachycardia	8 - Moderate	10 - Moderate	9 - Severe
		Energy Decrease	8 - Moderate		
	302	Headache	-3 - Moderate	2 - Moderate	
		Constipation	1 - Mild		
	303	Headache	3 - Moderate	5 - Mild	
		Upper Respiratory Infection	7 - Moderate		
		Coughing	8 - Mild	10 - Mild	
	305	Flu Symptoms	-2 - Moderate		
		Upper Respiratory Infection	-1 - Moderate	8 - Moderate	
		Chest Pain	1 - Moderate	6 - Severe	
		Headache	3 - Moderate	6 - Moderate	
		Dyspnea	7 - Mild		
		Eyelid Disorder	9 - Moderate		
	307	Eyes, Red/Inflam	-3 - Moderate		
		Sinusitis/Sinus Inflam	-2 - Mild	3 - Moderate	
		Vomiting	-2 - Moderate	4 - Moderate	
		Coughing	-1 - Mild	1 - Mild	
		Headache	2 - Moderate	10 - Moderate	
		Nausea	4 - Moderate		
		Diarrhea	4 - Moderate		
		Dizziness	5 - Mild	7 - Mild	

*Presented only if there is a multiple occurrence.

**Presented only if different from information recorded under first or last occurrence.

TABLE 30 (Continued)

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence*	Worst Occurrence**
PN 200-110	310	Diarrhea	-3 - Mild	1 - Mild	
		Dizziness	-3 - Mild	2 - Mild	
		Dyspnea	3 - Moderate	6 - Moderate	
		Tachycardia	3 - Moderate	6 - Moderate	
		Headache	3 - Mild	6 - Moderate	
		Flushing	6 - Moderate		
	311	Fatigue	1 - Moderate		
		Head & Chest Cold	2 - Moderate	3 - Moderate	
		Abdominal Discomfort	4 - Mild	7 - Moderate	
		Diarrhea	4 - Mild		
	314	Tooth Extraction	-3 - Moderate		
		Coughing	-3 - Mild	5 - Mild	
		Shoulder Pain	-2 - Moderate		
		Dizziness	-1 - Mild	4 - Mild	
		Palpitations	3 - Moderate	4 - Moderate	
		Vaginal Itch	4 - Moderate	5 - Moderate	
		Chest Pain	5 - Moderate		
		Tachycardia	5 - Moderate		
	316	Shoulder Pain	-3 - Moderate	10 - Moderate	7 - Severe
	353	Upper Respiratory Infection	-1 - Moderate	1 - Mild	
		Coughing	2 - Mild		
		Eyelid Disorder	3 - Mild		
		Abdominal Discomfort	5 - Moderate	6 - Moderate	
		Constipation	9 - Moderate		
	355	Abdominal Discomfort	-1 - Severe	7 - Moderate	
		Nausea	-1 - Moderate		
	402	Headache	-3 - Moderate	9 - Moderate	
		Abdominal Discomfort	-3 - Mild		
		Edema	3 - Mild	10 - Mild	
		Laceration	8 - Mild		
	403	Chest Pain	2 - Mild		

*Presented only if there is a multiple occurrence.

**Presented only if different from information recorded under first or last occurrence.

TABLE 30 (Continued)

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence*	Worst Occurrence**
PN 200-110	405	Headache	-3 - Moderate	10 - Mild	
		Fatigue	-3 - Moderate	8 - Mild	
		Eyes, Burning	-2 - Mild	2 - Mild	
		Photophobia/Photosens.	-1 - Mild		
		Stools, Loose	3 - Mild		
		Flu Symptoms	5 - Mild		
		Coughing	7 - Mild	8 - Mild	
		Flushing	7 - Mild		
	408	Back, Ache/Pain, etc.	1 - Mild		
	410	Coughing	-2 - Mild	7 - Mild	
		Head, Misc.Abnormality	8 - Mild		
	412	Teeth, Ache/Pain, etc.	-3 - Mild	-1 - Mild	
		Headache	-3 - Mild	8 - Mild	
		Irritability	-3 - Mild	6 - Mild	
		Drowsy	1 - Mild	10 - Mild	
		Dizziness	2 - Mild	8 - Mild	
		Chills	3 - Mild	10 - Mild	
		Nose Running/Rhinorrhea	3 - Mild	10 - Mild	
		Back, Pain/Ache, etc.	6 - Mild	7 - Mild	
		Nasal Congestion	8 - Mild	10 - Mild	
		Insomnia	8 - Mild	10 - Mild	
		Scalp, Any Abnormality	9 - Mild		
		Coughing	9 - Mild	10 - Mild	
	414	Cold	4 - Mild	5 - Mild	
		Impotence	4 - Mild	5 - Mild	
	415	Cold	-2 - Mild	1 - Mild	
		Pollakiuria	3 - Mild	4 - Mild	
	452	Cold Symptoms	2 - Mild	4 - Mild	

*Presented only if there is a multiple occurrence.

**Presented only if different from information recorded under first or last occurrence.

TABLE 30 (Continued)

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence*	Worst Occurrence**
Propranolol	104	Edema	1 - Mild	7 - Mild	
	106	High Sugar Glucose	7 - Mild	10 - Mild	
	201	Hypokalemia	-3 - Moderate	-1 - Moderate	
		Loose Stools	-1 - Mild		
	208	Tachycardia	-2 - Mild		
		Shoulder Pain	5 - Severe		
	210	Impotence	4 - Moderate	7 - Mild	
		Back, Ache/Pain, etc.	7 - Moderate		
		Hemoptysis (Blood Spitting)	7 - Moderate		
	211	Skin Lesion	-1 - Moderate	2 - Moderate	
	214	Achalasia	-1 - Mild		
	255	Chest Pain	-2 - Mild		
		Impotence	10 - Severe		
	301	Pruritus	-3 - Moderate	10 - Moderate	
		Syncope	4 - Mild		
		Chest Pain	9 - Moderate		
	306	Headache	-3 - Moderate	6 - Mild	
		Trichomonas/Fungus	-2 - Moderate		
		Temp ABN	2 - Moderate	3 - Moderate	
		Weakness	2 - Moderate	3 - Mild	
		Upper Respiratory Infection	3 - Moderate		
		Impotence	5 - Severe		
		Face Pressure	7 - Moderate		
	308	Nausea	-3 - Moderate	10 - Mild	
		Headache	-3 - Mild	10 - Mild	
		Fatigue	-1 - Mild	4 - Mild	
		Abdominal Discomfort	1 - Mild		
		Dizziness	3 - Mild	5 - Mild	
		Ear Disorders	6 - Mild	8 - Mild	
		Back, Ache/Pain, etc.	6 - Mild		
		Arthritis	8 - Mild	10 - Mild	

*Presented only if there is a multiple occurrence.

**Presented only if different from information recorded under first or last occurrence.

TABLE 30 (Continued)

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence+	Worst Occurrence++
Propranolol	309	Chest, Burning In	-3 - Moderate		
		Feet, Burn/Pain/Ache	2 - Severe	10 - Mild	
		Cold Symptoms	5 - Moderate		
		Hands/Feet, Ache/Pain	6 - Mild		
	312	Abdominal Discomfort	-3 - Mild	3 - Mild	
		Dizziness	-3 - Mild	3 - Mild	
	313	Cramps, Muscle	-3 - Mild	-2 - Mild	
		Rash	-1 - Mild	1 - Mild	
		Dizziness	1 - Mild		
		Fatigue	2 - Mild	8 - Mild	
		Diarrhea	3 - Moderate		
	315	Fatigue	-1 - Mild	7 - Moderate	4 - Moderate
		Painful Right Knee	2 - Severe	3 - Mild	
		Depression/Ennui	6 - Mild	7 - Mild	
	351	Cramp, Muscle	1 - Moderate		
		Teeth, Ache/Pain	4 - Moderate	5 - Moderate	
		Abdominal Discomfort	5 - Moderate		
		Loose Stools	5 - Moderate		
	354	Cramps Leg/Feet	-2 - Moderate		
		Cold	1 - Mild	10 - Mild	
	401	Headache	-2 - Mild	4 - Mild	
		Nausea	1 - Mild	4 - Moderate	
	404	Abdominal Discomfort	-3 - Mild		
		Chest Pain	-1 - Moderate		
		Cold Symptoms	2 - Moderate	6 - Mild	
		Dry Mouth	5 - Mild	6 - Mild	
		Constipation	5 - Mild	7 - Mild	
		Nausea	7 - Mild		
		Fatigue	7 - Mild		
		Rash	10 - Moderate		

+Presented only if there is a multiple occurrence.

++Presented only if different from information recorded under first or last occurrence.

TABLE 30 (Continued)

PN 200-110 STUDY NO. 307

ADVERSE REACTION LISTING

Treatment Group	Patient No.	Adverse Reaction	Week And Severity Of		
			First Occurrence	Last Occurrence*	Worst Occurrence**
Propranolol	406	Flushing	-3 - Mild	-2 - Mild	
		Fatigue	1 - Mild	3 - Mild	
		Dizziness	1 - Mild	6 - Moderate	
		Headache	2 - Mild		
	407	Cold Symptoms	-3 - Mild	7 - Mild	
		Headache	-1 - Mild		
	409	Headache	-2 - Moderate		
		Cold Symptoms	10 - Mild		
	411	Back, Ache/Pain, etc.	-2 - Mild	10 - Mild	
		Throat Discomfort	-1 - Mild	4 - Mild	
		Nose Running/ Rhinorrhea	-1 - Mild	4 - Mild	
		Nasal Congestion	-1 - Mild	1 - Mild	
		Body Feelings, Misc.	1 - Mild		
		Rash	1 - Mild		
		Abdominal Discomfort	3 - Mild	4 - Mild	
		Headache	3 - Mild		
		Hand/Feet, Pain/Ache, etc.	5 - Mild		
		Fingernails, Brittle/Dry	6 - Mild	8 - Mild	
		Fatigue	6 - Mild	8 - Mild	
		Incision Pain	7 - Mild		
	413	Drowsy	-3 - Mild	5 - Mild	
		Cellulitus Left Leg	-2 - Mild	1 - Mild	
		Cold	10 - Mild		
		Eye Discomfort	-2 - Mild	-1 - Mild	
		Throat, Pain/Numb/ Ache/Discom/etc.	-2 - Mild	-1 - Mild	
		Abdominal Discomfort	5 - Mild	6 - Mild	
		Headache	6 - Mild		
		Arms, Misc. Abnorm.	7 Mild	8 - Mild	
		Neck, Pain/Sore/ Stiff, etc.	8 - Mild		
	451	Headache	-1 - Mild	3 - Moderate	
		Gagging	3 - Mild		
		Nausea	3 - Mild	7 - Moderate	
		Abdominal Discomfort	7 - Moderate		

*Presented only if there is a multiple occurrence.

**Presented only if different from information recorded under first or last occurrence.

TABLE 31
PN 200-110 STUDY NO. 307

COMPARATIVE ADVERSE REACTION FREQUENCIES
ADJUSTED FOR BASELINE EFFECTS
(WEEKS 1-10)

Adverse Reaction	Treatment Group		p-value from Fisher's Exact Test
	PN 200-110 (N=40)	Propranolol (N=38)	
Miscellaneous			
Arms (misc. abnorm.)	0 (0.0)	1 (2.6)	0.49
Chills	1 (2.5)	0 (0.0)	1.00
Ears Disorder	0 (0.0)	1 (2.6)	0.49
Eyelid Disorder	2 (5.0)	0 (0.0)	0.49
Face, Pressure	0 (0.0)	1 (2.6)	0.49
Feet, Burn/Pain/Ache, Etc.	0 (0.0)	1 (2.6)	0.49
Temperature Abnormal	0 (0.0)	1 (2.6)	0.49
Teeth/Mouth Pain	1 (2.5)	1 (2.6)	1.00
Throat Discomfort	1 (2.5)	0 (0.0)	1.00
Body Feelings Misc.	0 (0.0)	1 (2.6)	0.49
Skin			
Fingernails/Brittle/Dry	0 (0.0)	1 (2.6)	0.49
Pruritus	1 (2.5)	0 (0.0)	1.00
Rash	1 (2.5)	2 (5.3)	0.61
Scalp, Any Abnormality	1 (2.5)	0 (0.0)	1.00
Hives	1 (2.5)	0 (0.0)	1.00
Musculo-Skeletal			
Back, Ache/Pain, etc.	2 (5.0)	2 (5.3)	1.00
Hand/Feet, Ache/Pain, Etc.	0 (0.0)	2 (5.3)	0.23
Joint Pain	1 (2.5)	0 (0.0)	1.00
Neck, Sore/Stiff/Pain, Etc.	0 (0.0)	1 (2.6)	0.49
Shoulder Pain	1 (2.5)	1 (2.6)	1.00
Respiratory			
Coughing	5 (12.5)	0 (0.0)	0.05(*)
Nose Running/Rhinorrhea	1 (2.5)	0 (0.0)	1.00
Nasal Congestion	1 (2.5)	0 (0.0)	1.00
Sinusit's/Sinus Inflam.	1 (2.5)	0 (0.0)	1.00
Cardiovascular			
Cardiac (misc. abnorm.)	1 (2.5)	0 (0.0)	1.00
Chest Pain	4 (10.0)	1 (2.6)	0.36
Dyspnea	2 (5.0)	0 (0.0)	0.49
Edema	5 (12.5)	1 (2.6)	0.20
Cramps, Leg/Feet	2 (5.0)	0 (0.0)	0.49
Cramps, Muscle	2 (5.0)	1 (2.6)	1.00
Palpitation	1 (2.5)	0 (0.0)	1.00
Tachycardia	4 (10.0)	0 (0.0)	0.12

(*)p<.10, *p<.05, **p<.01, ***p<.001

TABLE 31 (Continued)
PN 200-110 STUDY NO. 307

COMPARATIVE ADVERSE REACTION FREQUENCIES
ADJUSTED FOR BASELINE EFFECTS
(WEEKS 1-10)

Adverse Reaction	Treatment Group		p-value from Fisher's Exact Test
	PN 200-110 (N=40)	Propranolol (N=38)	
Hemic and Lymphic			
Hemoptysis (blood spitting)	0 (0.0)	1 (2.6)	0.49
Gastrointestinal			
Abdominal Discomfort	3 (7.5)	5 (13.2)	0.48
Constipation	2 (5.0)	1 (2.6)	1.00
Diarrhea	3 (7.5)	1 (2.6)	0.62
Gagging	0 (0.0)	1 (2.6)	0.49
Nausea	1 (2.5)	3 (7.9)	0.35
Stools, Loose	1 (2.5)	1 (2.6)	1.00
Vomiting	1 (2.5)	0 (0.0)	1.00
Urogenital			
Impotence	1 (2.5)	3 (7.9)	0.35
Pollakiuria	1 (2.5)	0 (0.0)	1.00
Vaginal Itch	1 (2.5)	0 (0.0)	1.00
Central Nervous System			
Weakness	0 (0.0)	1 (2.6)	0.49
Depression/Ennui	0 (0.0)	1 (2.6)	0.49
Dizziness	3 (7.5)	2 (5.3)	1.00
Drowsy	1 (2.5)	0 (0.0)	1.00
Energy Decrease	1 (2.5)	0 (0.0)	1.00
Fatigue	1 (2.5)	5 (13.2)	0.10
Headache	6 (15.0)	4 (10.5)	0.74
Head (misc. abnorm.)	1 (2.5)	0 (0.0)	1.00
Insomnia	1 (2.5)	0 (0.0)	1.00
Syncope	0 (0.0)	1 (2.6)	0.49
Autonomic Nervous System			
Flushing	3 (7.5)	0 (0.0)	0.24
Dry Mouth	0 (0.0)	1 (2.6)	0.49
Visual Disturbance	1 (2.5)	0 (0.0)	1.00
Total No. of Patients with an Adverse Reaction	29 (72.5)	17 (44.7)	0.02*

(*)p<.10, *p<.05, **p<.01, ***p<.001

Figure 1

PN 200-110 STUDY #307
Supine Systolic BP
Change from Baseline
Valid Patients
(n=61)



Figure 2

PN 200-110 STUDY #307
Supine Diastolic BP
Change from Baseline
Valid Patients
(n=61)



0540
07-02544

Figure 3

PN 200-110 STUDY #307
Supine Pulse
Change from Baseline
Valid Patients
(n=61)



Figure 4

PN 200-110 STUDY #307
Standing Systolic BP
Change from Baseline
Valid Patients
(n=61)



Figure 5

PN 200-110 STUDY #307
Standing Diastolic BP
Change from Baseline
Valid Patients
(n=61)



Figure 6

PN 200-110 STUDY #307
Standing Pulse
Change from Baseline
Valid Patients
(n=61)



Title:

25

A Dou
Oral]
Place

Safety and Dose Toleration of
mpound PN 200-110 Compared with
teers

Investigator:

Albert Cohen, M.D.
Peninsular Testing Corporation
20215 N.W. 2nd Ave, suite 3
Miami, Fl 33169.

Objective:

To assess the safety of five, graded, single oral doses of PN 200-110 (2.5 mg, 5 mg, 10 mg, 15 mg and 20 mg) compared to placebo in a group of 50 healthy, male volunteers.

Subject Selection:

Population group consisted of healthy, male subjects, 18 - 45 years of age. Subjects were to have normal vital signs, ECGs and laboratory values. Any one with significant clinical illness within two weeks prior to the study was excluded. Additional exclusion criteria were subjects who had received any investigational drug in previous four weeks, required any concomitant medication, history of alcohol or drug abuse within previous year, intolerance to calcium antagonists or any condition that could interfere in evaluation of the drug.

Trial Plan:

This was a randomized, double-blind, parallel group, placebo controlled study with 50 evaluable subjects. Medication was supplied as identically appearing capsules containing either 2.5 mg PN 200-110 or placebo.

After satisfying entry criteria, subjects were randomly assigned to a group and drug was administered at 8.00 a.m. All subjects remained at the study site for the duration of the trial. There were five escalating doses used, 2.5 mg, 5 mg, 10 mg, 15 mg and 20 mg. Each stage consisted of ten subjects and each subject received only one dose of medication. Subjects were evaluated for 32 hour period and safety of each dose was assessed prior to proceeding to next stage. Apparantly this procedure was followed until the maximum tolerated dose was reached.

Study medication (1, 2, 4, 6 or 8 capsules) was administered at 8.00 a.m. while subjects were fasting. No food was given until 2 hour post dose vital sign evaluation had been completed.

Vital sign evaluation included body weight, oral body temperature, respiratory rate, sitting and standing blood pressures and radial pulse. The first two parameters were measured at screening visit, before and 24 hours after dosing. Sitting blood pressure, pulse and respiratory rates were recorded at screening, prior to dosing and 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 32 hours post dose. Standing blood pressure and pulse were evaluated at screening, prior to dose and 1, 2, 4 and 12 hours post dose. Clinical laboratory evaluations were done pre and 24 hours post dose. ECGs were also recorded.

Results:

A total of 50 subjects completed the study. There were 8 subjects in each group receiving active madication and two per group receiving placebo. The groups were comparable for all demographic characteristics.

There were no changes in physical examination pre and post study. Tables 3 and 4 present vital sign data. In both sitting and standing positions, there were statistically significant reductions from baseline in diastolic blood pressure 1-2 hours post dose in 10, 15 and 20 mg groups and 4 hours post dose in 20 mg group. Changes appear to be dose related and are statistically significantly different from placebo at 1 and 2 hours post dose.

Mean Change in Diastolic Blood Pressure from Baseline

Group	Sitting Hours Post-Dose			Standing Hours Post-Dose		
	1	2	4	1	2	4
10 mg	-4.8	0	- 0.5	- 8.0	-9.8	-3.8
15 mg	-7.3	-13.0	- 4.3	-13.3	-10.0	-6.0
20 mg	-9.0	-15.1	-12.3	- 8.3	-15.1	-12.3
Placebo	-0.8	- 2.6	- 5.4	- 3.4	- 3.6	- 7.6

Mean Change in Pulse Rate from Baseline

10 mg	+ 2.0	0	+ 8.5	- 1.5	- 3.0	+ 8.0
15 mg	+ 1.0	+4.0	+ 5.0	+ 2.0	+ 4.3	+13.5
20 mg	+13.3	+11.5	+15.0	+14.0	+13.1	+13.7
Placebo	- 2.2	- 0.4	+ 6.4	- 8.8	- 5.2	+ 7.2

These decreases in diastolic pressures were not accompanied by similar reductions in systolic pressure but were accompanied by increases in pulse rate which were statistically significant for 20 mg group. In those subjects receiving 10 mg or less, there was no dose response relationship. There were a few subjects with pulse rates > 100 bpm in the 15 and 20 mg groups. These occurred in the standing position and lasted 6 hours post dose

No subject had a systolic blood pressure of less than 90 mm Hg. There were no clinically significant differences between active groups and placebo for body weight and body temperature.

ECGs:

ECGs were recorded at screening and 2, 4, 8 and 24 hours post dose. Tables 6 and 7 present ECG data and frequency of rhythm abnormalities respectively. In the 20 mg group, there was an increase in atrial and ventricular rates with statistical significance from baseline 1 - 8 hour post dose and from placebo 2 hours post dose. In the 10 mg group, there was a statistically significant increase from baseline in PR interval up to 24 hours and in 15 mg group 8 hours post dose. The 5 mg group had a statistically significant increase from baseline in QRS duration (0.014 - 0.019 sec). There was no overall dose related changes in PR intervals, QT intervals and QRS durations.
There were rhythm abnormalities noted in a number of subjects (Table 7). There was no between group differences. Sinus bradycardia (heart rate < 60 bpm) was listed for all patients.

Clinical Laboratory Results.

Laboratory evaluations were done at screening and 24 hours post dose. Results are given in Tables 8 - 10. Although there were statistical changes in a number of parameters, there was no dose relationship seen, except for BUN at the two highest doses. There were also significant changes in blood glucose and LDH.

Adverse Reactions

Table 16 lists all ADRs during the study. No subject discontinued due to an ADR. The most commonly reported events were dizziness and headache. There appears to be a dose relationship for these events. Table 17 shows comparative frequency of ADRS and Table 18 those reporting at least one event.

Discussion

There were 50 subjects entered into this study. There were few side effects. The most commonly reported ADRs were dizziness and headache and these seemed dose related. With 15 and 20 mg there were changes in diastolic blood pressure and pulse but no orthostatic changes. Sponsor concludes that PN 200-110 is safe when administered as a single dose and that 20 mg is not as well tolerated as lower doses.

TABLE 3

PN 200-110 STUDY 01

VITAL SIGNS

SITTING BLOOD PRESSURE, PULSE, AND RESPIRATION RATE
ANALYSES OF VARIANCE[1]

Variable	Treatment Group	N	Baseline Mean (Pre-Dose)	Mean Change From Baseline At Hours Post-Dose: Hour .5	Hour 1	Hour 2	Hour 4	Hour 6	Hour 8	Hour 10	Hour 12	Hour 24	Hour 32	Mean Change Over Hours .5–32
Systolic Blood Pressure (mm Hg)	2.5 mg	8	105.5	1.0	0.5	-1.5	4.5	10.0(*)	5.0	6.0	6.8	7.0(*)	9.0	4.9
	5.0 mg	8	109.0	2.3 (†)	2.8	3.5	0.0	7.5(*)	4.0	4.8	2.0	6.5*	9.3**	4.3 (*)
	10.0 mg	8	108.0	-1.0	0.3	-1.0	3.8	2.3	5.5	5.8**	4.3	-1.8	8.5*	2.7
	15.0 mg	8	117.8	-1.0	-5.0	-5.8	-0.3	-1.5	0.0	-0.8	-1.0	-3.0	4.8	-1.4
	20.0 mg	8	110.3	-0.5	0.5	3.5	2.5	6.0*	3.5(*) (†)	4.0	7.3*	2.0	6.8*	3.6*
	Placebo	10	114.4	-4.8(*)	-5.6(*)	-7.2*	-4.8	-1.6	-6.0 (†)	-3.4 (†)	-4.6	-4.8(†)	3.0	-4.0 (†)
Diastolic Blood Pressure (mm Hg)	2.5 mg	8	69.8	2.5	0.3	0.8	3.0	2.3	1.0	6.0	5.0(*)	1.3	6.0	2.8
	5.0 mg	8	70.3	3.0*	2.5	4.8**	1.0	4.5*	2.0	3.0(*)	2.5	3.0	5.5**	3.2*
	10.0 mg	8	68.0	-2.1 **	-4.8* **	0.0	-0.5	2.0	3.5	2.8	3.0	7.0(*)	9.3*	2.0 (†)
	15.0 mg	8	69.3	1.8	-7.3* **	-13.0**	-4.3	1.0	2.0	2.3 **	1.5	0.0	6.3(*)	-1.0
	20.0 mg	8	73.0	-2.5(*)	-9.0 **	-11.0 **	-6.8*	-3.0	-2.8	-3.3	3.0	-5.3	0.3	-4.0
	Placebo	10	73.6	1.0	-0.8 **	-2.6 **	-5.4*	-4.6*	-4.8(*)	-5.2*	-4.4	-2.0	0.4	-2.8
Pulse (per min.)	2.5 mg	8	67.5	1.0	1.0	4.0	6.5(*)	7.0	5.0	3.5	7.5*	2.5	6.5(*)	4.5
	5.0 mg	8	72.0	-6.0*	-2.5	-3.5	2.0	3.5	2.8	4.0	5.0	1.5	5.0	1.2
	10.0 mg	8	68.0	0.5	2.0	0.0	8.5*	8.5*	6.0*	4.0(*)	9.0**	1.0	3.3*	4.5*
	15.0 mg	8	69.5	-4.0	1.0	4.0	5.0	7.0(*)	3.0	3.5	4.5	-0.5 (†)	5.5 (†)	2.9
	20.0 mg	8	67.5	2.0	13.5*	11.5(*)	15.0*	13.0*	7.5	3.5	10.0*	-1.0	5.5 (*)	8.0(*)
	Placebo	10	66.4	0.4	-2.2 **	-0.4	6.4*	8.4*	5.2(*)	3.6*	6.4*	-0.4	12.5**	3.9* (†)
Respiration Rate (per min.)	2.5 mg	8	15.5	0.6(*)	0.5	0.5	0.5	0.0	0.5	0.3	0.3	0.5	0.8(*)	0.4
	5.0 mg	8	15.8	0.3	0.3	0.3	0.5	0.3	0.3	-0.5	0.3	0.3	0.3	0.2
	10.0 mg	8	16.0	-0.5	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.0	0.0
	15.0 mg	8	16.0	0.0	0.0	0.0	0.0 (†)	0.0 (†)	0.0	0.0	0.0 (†)	0.0	0.0	0.0
	20.0 mg	8	16.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	Placebo	10	16.2	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2	-0.4	-0.4	-0.2	-0.4	-0.3

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$

[1]Standard deviations and additional descriptive statistics can be found in the Statistical Appendix.

TABLE 3

0548

TABLE 4

FN 200-110 STUDY #1

VITAL SIGNS

STANDING BLOOD PRESSURE AND PULSE
ANALYSIS OF VARIANCE†

Variable	Treatment Group	N	Baseline Mean (Pre-Dose)	Mean Change From Baseline At Hours Post-Dose				Mean Change Over Hours 1-12
				Hour 1	Hour 2	Hour 4	Hour 12	
Systolic Blood Pressure (mm Hg)	2.5 mg	8	110.3	-3.5(*)	-0.5	7.5(*)	5.3	2.2
	5.0 mg	8	113.8	-0.3	0.5	1.5	6.0	1.9
	10.0 mg	8	111.3	1.5	-3.5 *	4.5 (*)	6.5*	2.3
	15.0 mg	8	114.3	-4.3	-0.5	-0.3	3.3	-0.4
	20.0 mg	8††	115.0	-3.8	-0.9(*)	-0.9	2.8	-1.3
	Placebo	10	113.4	-3.0	-7.0*	-2.8	1.4	-2.9
lic Blood ure (mm Hg)	2.5 mg	8	77.3	-3.3	-3.0	1.3	3.8(*)	-0.3
	5.0 mg	8	77.0	-2.3	0.3	-3.5	3.0 (*)	-0.6
	10.0 mg	8	76.0	-8.0*	-9.8*	-3.8	0.3	-5.3
	15.0 mg	8	76.8	-13.3** (*)	-10.0**	-6.0	-2.8(*)	-8.0**
	20.0 mg	8††	79.3	-8.3(*) **	-15.1** *	-12.3*	0.0	-7.1 *
	Placebo	10	80.4	-3.4	-3.6 *	-7.6(*)	-3.4(*)	-4.5(*)
Pulse (per min)	2.5 mg	8	75.5	0.0	0.5	11.0(*)	8.5*	5.0
	5.0 mg	8	81.0	-1.0	-5.5	1.5	3.5	-0.4
	10.0 mg	8	78.0	-1.5	-3.0	8.0(*)	6.0	2.4
	15.0 mg	8	78.5	2.0	4.3	13.5*	2.0	5.4
	20.0 mg	8††	77.5	14.0(*) (*)	13.1(*) (*)	13.7*	4.5	11.0(*)
	Placebo	10	79.6	-8.8* ***	-5.2(*)***	7.2*	6.8*	0.0 *

< .10, * p < .05, ** p < .01, *** p < .001

ndard deviations and additional descriptive statistics can be found in the Statistical Appendix.

††Subject 508 is missing evaluations at hour 2 and 4.

TABLE 6

PN 200-110 STUDY #1

ECG EVALUATION
ANALYSIS OF VARIANCE†

Variable	Treatment Group	N	Baseline Mean (Pre Dose)	Mean Change From Baseline At Hours Post-Dose				Mean Change Over Hours 2-24
				Hour 2	Hour 4	Hour 8	Hour 24	
Atrial Rate (per min.)	2.5 mg	8	56.00	-0.50	9.88*	6.25*	-0.75	3.72
	5.0 mg	8	59.75	2.25	7.75*	4.88(*)	0.63	3.88
	10.0 mg	8	57.63	-2.25	5.00	1.63	-1.63	0.69
	15.0 mg	8	63.25	-3.50	0.75	-5.50	0.00	-2.06
	20.0 mg	8	57.13	10.38** (*)	11.00** (*)	8.50*	-0.25 (*)	7.41**
	Placebo	10	57.30	-7.20**	3.90	3.00	-3.70**	-1.00
Ventricular Rate (per min.)	2.5 mg	8	56.00	-0.50	9.88*	6.25*	-0.75	3.72
	5.0 mg	8	59.75	2.25	7.75*	4.88(*)	0.63 (*)	3.88
	10.0 mg	8	57.63	-2.25	5.00	1.63	-1.63	0.69
	15.0 mg	8	63.25	-3.50 (*)	0.75	-5.50	0.00	-2.06
	20.0 mg	8	57.13	10.38**	11.00** (*)	8.50*	-0.25 (*)	7.41**
	Placebo	10	57.30	-7.20**	3.90	3.00	-3.70**	-1.00
PR Interval (sec.)	2.5 mg	8	0.161	0.009	-0.003	0.016*	0.006	0.007
	5.0 mg	8	0.165	0.010	0.009	0.010	0.010	0.010
	10.0 mg	8	0.157	0.021**	0.027**	0.015**	0.016*	0.020***
	15.0 mg	8	0.164	0.014 (*)	0.009(*) (*)	0.015*	0.010	0.012(*)
	20.0 mg	8	0.172	0.002	0.009	0.003 (*) (*)	0.004	0.006
	Placebo	10	0.169	0.000	0.006	0.001	0.002	0.002

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$

†Standard deviations and additional descriptive statistics can be found in the Statistical Appendix

TABLE 6 (cont'd)

PN 200-110 STUDY #1

ECG EVALUATION
ANALYSIS OF VARIANCE†

Variable	Treatment Group	N	Baseline Mean (Pre-Dose)	Mean Change From Baseline At Hours Post-Dose				Mean Change Over Hours 2-24
				Hour 2	Hour 4	Hour 8	Hour 24	
QRS Duration (sec.)	2.5 mg	8	0.072	0.005	0.004	0.005	0.003	0.004(*)
	5.0 mg	8	0.062	0.015**	0.019**	0.017**	0.014*	0.016**
	10.0 mg	8	0.071	0.004(*)	0.006(*)	0.001	0.005	0.004
	15.0 mg	8	0.067	0.009	0.011(*)	0.011(*)	0.009	0.010
	20.0 mg	8	0.081	-0.004(*)	-0.001	0.000	-0.001	-0.002(*)
	Placebo	10	0.071	0.008	0.007(*)	0.008	0.010	0.008
Interval (sec.)	2.5 mg	8	0.389	-0.015*	-0.006	-0.016(*)	0.021	-0.004
	5.0 mg	8	0.379	0.003	0.003	-0.005	-0.016**	-0.004
	10.0 mg	8	0.389	-0.007	-0.005	-0.011	-0.013*	-0.009
	15.0 mg	8	0.371	0.002	-0.006	0.011	0.006	0.003
	20.0 mg	8	0.389	0.000	0.003	-0.009	0.006	0.000
	Placebo	10	0.369	0.006	0.012	0.005	0.020	0.011

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$

†Standard deviations and additional descriptive statistics can be found in the Statistical Appendix.

TABLE 7

PM 200-119 STUDY #1

FREQUENCY OF SUBJECTS WITH ECG RHYTHM ABNORMALITIES*

Treatment Group	N	No. of Subjects with Rhythm Abnormalities at Screening	No. of Subjects with Normal Rhythm Throughout Study	Subjects with Newly Occurring Rhythm Abnormalities (Subject No.)	Heart Rate (bpm) Study Day 0	Heart Rate (bpm) Study Day* 1 and 2	Hours Post Dose
2.5 mg	8	5	0	101	65	58	2
				102	64	50	2
				107	63	57,57	2,4
5.0 mg	8	5	2	207	64	59	24
10.0 mg	8	4	1	302	63	48	2
				304	60	32	24
				310	64	54,59	2,24
15.0 mg	8	5	0	404	4	58	8
				405	61	55,58,57	2,8,24
				407	69	58	2
				408	62	59	8
				409	72	58	8
20.0 mg	8	6	1	509	62	59,57,55	2,8,24
Placebo	10	5	0	205	65	57	2
				303	63	45,58,59	2,8,24
				307	60	46,58,52	2,4,24
				403	63	56	2
				507	61	55,58	2,24

*Sinus bradycardia, defined as <60 beats/min. by the investigator, in all cases.

TABLE 8

PN 200-110 STUDY #1

LABORATORY DATA - HEMATOLOGY
ANALYSIS OF VARIANCE

Variable (Normal Range)	Treatment Group	No. of Subjects	Baseline Mean (Screening)	S.D.	Mean Change From Baseline (Day 2)	S.D.
HEMOGLOBIN gm/dl (14-18)	2.5 mg	8	14.9	0.90	0.66(*)	0.88
	5.0 mg	8	15.[illegible]	0.58	-0.48(*)	0.38
	10.0 mg	8	[illegible].7	0.91	0.15	0.42
	15.0 mg	8	15.6	1.39	0.08 (*)	0.56
	20.0 mg	8	15.3	0.90	-0.21	0.64
	Placebo	10	14.8	0.82	0.14	1.05
HEMATOCRIT % (42-52)	2.5 mg	8	42.6	1.92	2.13(*)	2.90
	5.0 mg	8	43.3	1.98	-1.00	2.20
	10.0 mg	8	44.6	2.77	2.50**	1.77
	15.0 mg	8	45.1	4.76	0.50	1.69
	20.0 mg	8	44.6	1.85	0.75 (*)	2.19
	Placebo	10	42.7	2.21	0.70	3.30
WBC x10^3 cc-mm (4.8-10.8)	2.5 mg	8	6.[illegible]	1.37	1.11*	1.29
	5.0 mg	8	5.6	1.15	0.11	0.96
	10.0 mg	8	6.8	2.17	0.51	1.73
	15.0 mg	8	6.2	0.95	0.50(*)	0.75
	20.0 mg	8	6.4	1.96	0.8[illegible](*)	1.00
	Placebo	10	6.1	0.75	0.55	0.96

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$

TABLE 8 (cont'd)

PN 200-110 STUDY #1

LABORATORY DATA - HEMATOLOGY
ANALYSIS OF VARIANCE

Variable (Normal Range)	Treatment Group	No. of Subjects	Baseline Mean (Screening)	S.D.	Mean Change From Baseline (Day 2)	S.D.
BANDS % (0-8)	2.5 mg	8	2.0	1.69	-0.38	1.77
	5.0 mg	8	2.3	1.17	-0.25	1.58
	10.0 mg	8	2.0	0.54	1.50*	1.69
	15.0 mg	8	1.5	1.07	2.00*	2.00
	20.0 mg	8	3.3	1.04	0.00 (*)(*)	1.60
	Placebo	10	3.5	2.59	-1.30	2.95
NEUTROPHILS % (50-75)	2.5 mg	8	59.3	6.14	-6.63**	4.07
	5.0 mg	8	55.8	6.14	-5.75	9.35
	10.0 mg	8	66.5	6.55	-4.38(*)	5.90
	15.0 mg	8	63.1	4.94	-6.38**	4.47
	20.0 mg	8	53.6	4.57	-3.39	9.88
	Placebo	10	56.4	8.17	-1.60	10.91
LYMPHOCYTES % (20-40)	2.5 mg	8	33.6	5.53	6.38*	5.58
	5.0 mg	8	37.0	7.29	5.13	11.46
	10.0 mg	8	28.6	6.48	0.88	4.88
	15.0 mg	8	30.5	7.05	3.50	5.29
	20.0 mg	8	38.0	3.82	1.63	9.67
	Placebo	10	33.6	8.15	3.80	9.77

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$

TABLE 8 (cont'd)

PN 200-110 STUDY #1

LABORATORY DATA - HEMATOLOGY
ANALYSIS OF VARIANCE

Variable (Normal Range)	Treatment Group	No. of Subjects	Baseline Mean (Screening)	S.D.	Mean Change From Baseline (Day 2)	S.D.
MONOCYTES % (0-8)	2.5 mg	8	3.4	2.00	0.88	2.80
	5.0 mg	8	2.8	2.05	0.75	3.45
	10.0 mg	8	2.1	1.25	0.50	2.07
	15.0 mg	8	2.3	1.17	0.88	1.46
	20.0 mg	8	3.3	2.05	1.75 (•)	4.10
	Placebo	10	3.4	2.22	-0.10	2.85
EOSINOPHILS % (0-4)	2.5 mg	8	1.8	1.17	-0.25	1.98
	5.0 mg	8	2.3	2.25	0.13	1.73
	10.0 mg	8	0.8	1.04	1.38(•)	1.69
	15.0 mg	8	2.5	2.07	0.13	1.46
	20.0 mg	8	1.9	2.03	-0.23	1.83
	Placebo	10	3.0	1.76	-0.70	1.70
BASOPHILS % (0-2)	2.5 mg	8	0.0	0.00	0.00	0.00
	5.0 mg	8	0.0	0.00	0.00	0.00
	10.0 mg	8	0.0	0.00	0.13	0.35
	15.0 mg	8	0.1	0.35	-0.13	0.35
	20.0 mg	8	0.0	0.00	0.25	0.46
	Placebo	10	0.1	0.32	-0.10	0.32

(•) $p < .10$, • $p < .05$, •• $p < .01$, ••• $p < .001$

TABLE 9

PN 200-110 STUDY #1

LABORATORY DATA - URINALYSIS
ANALYSIS OF VARIANCE

Variable (Normal Range)	Treatment Group	No. of Subjects	Baseline Mean (Screening)	S.D.	Mean Change From Baseline (Day 2)	S.D.
SPECIFIC GRAVITY (1.001-1.035)	2.5 mg	8	1.017	0.009	-0.002	0.014
	5.0 mg	8	1.017	0.010	0.003	0.012
	10.0 mg	8	1.017	0.008	0.001	0.012
	15.0 mg	8	1.020	0.012	-0.004	0.014
	20.0 mg	8	1.020	0.005	0.001	0.009
	Placebo	10	1.016	0.009	0.000	0.012
pH (5-8)	2.5 mg	8	6.0	1.04	-0.25	1.31
	5.0 mg	8	6.2	1.13	-0.56	0.90
	10.0 mg	8	5.2	1.19	0.88(*)	1.25
	15.0 mg	8	5.6	0.82	0.69	1.10
	20.0 mg	8	6.3	1.03	0.06 (*) *	1.18
	Placebo	10	6.1	1.04	-0.50	1.20

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$

TABLE 10

PN 200-110 STUDY #1

LABORATORY DATA - CHEMISTRIES
ANALYSIS OF VARIANCE

Variable (Normal Range)	Treatment Group	No. of Subjects	Baseline Mean (Screening)	S.D.	Mean Change From Baseline (Day 2)	S.D.
CALCIUM mg/dl (8.5-10.8)	2.5 mg	8	9.7	0.23	0.04	0.34
	5.0 mg	8	10.0	0.40	-0.49**	0.33
	10.0 mg	8	10.2	0.44	-0.31*	0.34
	15.0 mg	8	10.0	0.35	0.06	0.33
	20.0 mg	8	10.1	0.30	-0.28	0.44
	Placebo	10	10.1	0.27	-0.35*	0.42
INORGANIC PHOSPHORUS mg/dl (2.5-4.5)	2.5 mg	8	3.1	0.28	0.88***	0.41
	5.0 mg	8	3.4	0.44	0.05	0.56
	10.0 mg	8	3.4	0.52	0.53*	0.62
	15.0 mg	8	3.3	0.29	0.39	0.66
	20.0 mg	8	3.3	0.37	0.76**	0.61
	Placebo	10	3.6	0.34	0.17	0.48

(*) $p < .10$, * $p < .05$, ** $p < .01$, *** $p < .001$